CBDKnocking out Inflammation in Heart disease CBD to the Rescue!

Knocking out Inflammation in Heart disease: CBD to the Rescue!

We are living in unprecedented times in modern medicine. People are asking for real answers and help with chronic conditions not adequately treated (or with unacceptable side effects) by our modern pharmaceutical therapies. Many modern chronic conditions have inflammation as an underlying cause of the manifested disease and could be improved by cannabis therapy.

Pharmaceutical therapies work to reduce cholesterol, lower blood pressure and improve blood glucose control, all implicated in heart disease; but all anti-inflammatory drugs come with a risk of serious adverse events making them often unjustifiable for long-term therapy. Thankfully, cannabis can reduce chronic inflammation implicated in heart disease.

‘How does THC and CBD work to reduce inflammation and protect our bodies from disease?’

Inflamed and scarred arteries create a plaque, or lesion, that is worsened by chronic inflammation. Overtime chronic inflammation causes further injury and the lesion can eventually rupture blocking major arteries damaging the heart or brain. This chronic inflammation is caused by immune cells that continuously release inflammatory molecules that can be inhibited by molecules of the cannabis plant, tetrahydrocannabinol (THC) and cannabidiol (CBD). CBD is the non-psychoactive (i.e. it doesn’t get you high) molecule found in cannabis. While both THC and CBD are found in cannabis and have powerful anti-inflammatory effects, too much THC can get one “high” causing euphoria, paranoia, or intoxication.

THC activates cannabinoid (CB1) receptors in the central nervous system and cannabinoid (CB2) receptors in the periphery reducing the amount of inflammatory molecules released by immune cells and other signaling systems that lead to inflammation. CBD, has little affinity for CB1 or CB2 receptors and exerts its anti-inflammatory effects by acting on ion channels and blocking metabolizing enzymes, increasing the body’s natural endocannabinoid, anandamide. Studies also show that CBD may have cardioprotective effect reducing the size of a heart attack and reducing injury.

‘Who should consider taking CBD to prevent inflammation and prevent chronic disease?’

Reducing chronic inflammation in the body could be the most important thing we do to improve our overall health. Anyone with a risk factor for cardiovascular disease, like high blood pressure, high cholesterol, obesity, or metabolic syndrome should consider a small dose of CBD oil or edible daily to reduce inflammation.

‘Is cannabis safe for people with risks factors for cardiovascular disease?’

No, not all cannabis is safe for everyone with heart disease. Moderate to high doses of THC can increase heart rate initially and subsequently slow heart rate and lower blood pressure known as orthostatic hypotension, resulting in dizziness upon standing. THC-dominant cannabis varieties are not recommended for persons with irregular heart rhythms, (e.g. uncontrolled atrial fibrillation) or unstable heart disease (e.g. angina).

Instead persons with unstable heart disease should consider taking a CBD-dominant cannabis variety like, Cannatonic, ACDC, or Charlotte’s Web. I like to have my patients start with 0.25 mLs to 0.5 mLs once or twice daily of CBD-dominant cannabis that provides 6.25 mg to 12.5 mg of CBD and 0.5 mg to 1 mg of THC per dose.

Cannabis varieties like, Blueberry Cheesecake, Candyland, and Lavender are higher in caryophyllene, a terpene found in cannabis that also reduces inflammation. However, these have a higher ratio of THC to CBD and would be recommended for prevention and not advised for persons with heart disease. Start with 0.1 mLs to 0.25 mLs of a 1:1 mixture providing 1mg to 2.5 mg of THC and CBD in the evening. At this low dose side effects of euphoria or intoxication are unlikely and become less so with chronic and consistent use. As well, equal amounts of CBD will reduce the side effects of THC.

Remember each person will require a unique dose. Start low and go slow. If you have short-term memory lapses, excessively dry mouth, episodes of dizziness or increased heart rate lower your dose. Medical cannabis is a valuable tool to improve symptoms and underlying causes of disease but should be recommended with the guidance of an experienced practitioner to make sure this therapy is right for you.

  1. O’Sullivan SE. Phytocannabinoids and the cardiovascular system. In: Pertwee RG. Ed. Handbook of cannabis. Oxford; U.K. Oxford University Press. 2014.
  2. Schwope DM, Bosker WM, Ramaekers JG, Gorelick DA, Huestis MA. Psychomotor performance, subjective and physiological effects and whole blood delta-9-tetrahydrocannabinol concentrations in heavy chronic cannabis smokers following acute smoked cannabis. Journal of Analytical Toxicology. 2012;36:405-12.

 

  1. Benowitz NL, Jones RT. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. Clinical Pharmacology & Therapeutics. 1981;21:214S-223S.

 

  1. Jacobus J, Goldenburg D, Wierenga CE, Tolentino NJ, Liu TT, Tapert SF. Altered cerebral blood flow and neurocognitive correlates in adolescent cannabis users. Psychopharmacology (Berlin). 2012;222:675-84.

 

  1. Bedi G, Cooper ZD, Haney M. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addiction Biology. 2013;18:872-81.

 

  1. Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannbinol ingestion. Clinical Pharmacology & Therapeutics. 1975;18:287-97.

 

  1. Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA. Safety and side effects of cannabidiol, a Cannabis sativa Current Drug Safety. 2011;6:237-49.

 

 

  1. Richards JR, et al. Cannabis use and acute coronary syndrome. Clinical Toxicology [Internet]. 2019 Mar [cited 2019 July 25]; Available from: DOI: 1080/15563650.2019.1601735

 

  1. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering Myocardial Infarction by marijuana. Circulation. 2001;103:2805-09.

 

  1. Mach F, Steffens S. The role of the endocannabinoid system in atherosclerosis. Journal of Neuroendocrinology [Internet]. Apr 2008 [cited 22 July 2019]; Available from: https://doi-org.proxy.lib.sfu.ca/10.1111/j.1365-2826.2008.01685.x

 

  1. Pacher P, Steffens S, Hasko G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nature Reviews Cardiology [Internet]. 2017 Sept [cited 2019 July 22]; Available from: https://www-nature-com.proxy.lib.sfu.ca/articles/nrcardio.2017.130

 

  1. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol. Nov 2002;42(S1):11S-19S.

 

  1. MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. European Journal of Internal Medicine. 2018;49:12-19.

 

  1. Shayesteh MRH, Haghi-Aminijan H, Mousavi MJ, Momtaz S, Abdollahi M. The protective mechanism of cannabidiol in cardiac injury: a systematic review of non-clinical studies. Curr Pharm Des [Internet]. July 2019[cited 23 July 2019]; Available from: https://www-ncbi-nlm-gov.proxy.lib.sfu.ca/pubmed/31291873

 

  1. Waslh SK, Hepburn CY, Kane KA, Wainwright CL. Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br J Pharmacology [Internet]. June 2010[cited 2 Aug 2019]; Available from: https://doi.org/10.1111/j.1476-5381.2010.00755.x

Leave a Reply

Your email address will not be published. Required fields are marked *